Edwards Reports TAVR Sales Progress In U.S. And Abroad

Edwards Lifesciences reported 19 percent year-over-year growth in worldwide sales of its Sapien transcatheter aortic valve systems during the second quarter of 2014. The company cites the ongoing launch of the Sapien 3 system in Europe and Sapien XT in the U.S. as keys to continuing growth.

Edwards Lifesciences Corp.says its recent launches of the Sapien 3 in Europe and Sapien XT in the U.S. are helping to expand the transcatheter aortic valve replacement patient population while helping Edwards keep its leadership in the TAVR market.

The company reported July 29 that its global transcatheter valve sales grew about 19 percent during the second quarter of...

More from Archive

More from Medtech Insight